新股首日 | 赛生药业午后翻红涨超2%
uSMART盈立智投3月3日消息,上市首日,赛生药业低开低走,午后由跌转涨,截至13:52分,赛生药业盘中涨超2%。
相较诺辉健康-B的逾100万人申购,赛生药业的申购人数约43.6万,公开认购倍数为1,068.05倍,国配认购倍数10倍,在目前动辄几十倍的国配数据下,国配认购算不上火爆。
赛生药业的乙组认购倍数高达1570倍,是甲组(566倍)的近3倍。乙组继续呈"内卷"趋势。
赛生药业的国配货源集中,合共211名承配人,前25名承配人合共锁定58.41%的发行股份,其中,上药国际等11名基石合共锁定47.53%的发行股份,禁售期6个月。也就是说,流动股份主要掌握在50%的公开散户手中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.